chronic lymphocytic leukemia

Type: Keyphrase
Name: chronic lymphocytic leukemia
First reported 2 hours ago - Updated 31 mins ago - 3 reports

Roche says Gazyvaro approved in Europe against leukemia | Reuters

5:53am EDT ZURICH (Reuters) - Roche said on Tuesday that European regulators approved its drug Gazyvaro, or obinutuzumab, for patients with chronic lymphocytic leukemia, boosting the Swiss group's line-up of new cancer treatments.The new medicine is an ... [Published DailyMe.Com - 46 mins ago]
First reported 2 hours ago - Updated 2 hours ago - 1 reports

FDA expands approved use of Imbruvica for chronic lymphocytic leukemia

Release date- 28072014 - The U.S. Food and Drug Administration today expanded the approved use of Imbruvica (ibrutinib) to treat patients with chronic lymphocytic leukemia (CLL) who carry a deletion in chromosome 17 (17p deletion), which is associated ... [Published Town Hall - 2 hours ago]
First reported 20 hours ago - Updated 10 hours ago - 11 reports

FDA Expands Approved Use of Imbruvica for Chronic Lymphocytic Leukemia

-- The U.S. Food and Drug Administration today expanded the approved use of Imbruvica (ibrutinib) to treat patients with chronic lymphocytic leukemia (CLL) who carry a deletion in chromosome 17 (17p deletion), which is associated with... ... [Published Drugs.com - 10 hours ago]
First reported Jul 28 2014 - Updated 14 hours ago - 1 reports

European CHMP adopts positive opinion for Gilead’s Zydelig to treat chronic lymphocytic leukemia and follicular lymphoma

Gilead Sciences has announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion on the company’s Marketing Authorization Application (MAA) for ... [Published PBR - News - Jul 28 2014]
First reported 14 hours ago - Updated 14 hours ago - 1 reports

In Europe, two drugs will compete to treat rare blood cancer

In Europe, two Bay Area pharmaceutical companies will go head-to-head over new drugs that both treat a rare blood cancer, chronic lymphocytic leukemia, in patients whose disease has returned. Last week, Gilead Sciences of Foster City won federal approval ... [Published Tech Chronicles - 14 hours ago]
First reported Jul 28 2014 - Updated Jul 28 2014 - 1 reports

EMA’s CHMP backs approval of two new treatment options for rare cancers

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP), at its July meeting, backed the granting marketing authorizations for two new drugs with novel mechanisms of action for the treatment of different forms of rare cancers ... [Published Pharma Letter - Jul 28 2014]
First reported Jul 27 2014 - Updated Jul 27 2014 - 1 reports

FDA approves Gilead Sciences’ Zydelig for three types of blood cancers

Gilead Sciences has obtained US Food and Drug Administration (FDA) approval for its Zydelig (idelalisib) 150mg tablets for treatment of three B-cell blood cancers.Zydelig is an oral inhibitor of phosphoinositide 3-kinase (PI3K) delta and can be used to ... [Published Pharmaceutical Technology - Jul 27 2014]
First reported Jul 25 2014 - Updated Jul 25 2014 - 5 reports

European CHMP Adopts Positive Opinion for Gilead’s Zydelig® (idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma

European CHMP Adopts Positive Opinion for Gilead’s Zydelig® (idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma ... [Published Nasdaq - Jul 25 2014]
First reported Jul 25 2014 - Updated Jul 25 2014 - 2 reports

Europe backs new leukemia drugs from J&J, Gilead

By Reuters StaffLONDON (Reuters) - Two new leukemia drugs from Johnson & Johnson and Gilead Sciences have been recommended for approval by European regulators, paving the way for formal approval in a couple of months.The European Medicines Agency said ... [Published MedCity News - Jul 25 2014]
First reported Jul 24 2014 - Updated Jul 25 2014 - 3 reports

FDA approves idelalisib for the treatment of patients with relapsed chronic lymphocytic leukemia

The U.S. Food and Drug Administration (FDA) has approved idelalisib (Zydelig tablets, GileadSciences, Inc.) for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, for whom rituximab alone would be ... [Published Ecancer Medicalscience - Jul 25 2014]
First reported Jul 23 2014 - Updated Jul 24 2014 - 4 reports

Zydelig approved for three types of blood cancer

(HealthDay)—Zydelig (idelalisib) has been approved by the U.S. Food and Drug Administration to treat relapsed forms of blood cancer, including chronic lymphocytic leukemia (CLL), follicular B-cell non-Hodgkin lymphoma (FL) and small lymphocytic lym.. ... [Published BioPortfolio - Jul 24 2014]
First reported Jul 23 2014 - Updated Jul 24 2014 - 10 reports

FDA Approves New Cancer Medication

Zydelig approved to treat certain blood cancersJuly 23, 2014 / Author: / Reviewed by: Joseph V. Madia, MDRate This ArticleAverage Rating3.85Your Rating(dailyRx News) The US Food and Drug Administration (FDA) approved Zydelig (idelalisib) today to treat ... [Published Daily Rx - Jul 24 2014]

Quotes

"Gazyvaro is a new option that helps patients achieve deep responses to treatment that translate to longer lasting remissions" says Sandra Horning, Roches's CMO and head of global product development
"We believe that modulating the immune system by targeting PD-L1 represents a promising new approach in the treatment of this aggressive cancer, especially considering that many of the predisposing factors for mMCC seem to be related to functional disruptions of the immune system" said Helen Sabzevari
...immune system," said Helen Sabzevari, Senior Vice President of Immuno-Oncology at the biopharmaceutical division of Merck KGaA, Darmstadt, Germany. "Our anti-PD-L1 compound may present a potential new approach for the treatment of mMCC patients. The initiation of this Phase II study is an important milestone, as we endeavor to help those suffering from mMCC, a devastating disease with significant unmet need."
"We are proud to make Gazyvaro available for CLL patients in Europe" said Sandra Horning, M D , Roche's Chief Medical Officer and Head, Global Product Development...

More Content

All (400) | News (302) | Reports (0) | Blogs (86) | Audio/Video (0) | Fact Sheets (1) | Press Releases (10)
sort by: Date | Relevance
Fairchild Semiconductor, E*Trade Financial, Gil... [Published Yahoo! Finance - 32 mins ago]
Roche says Gazyvaro approved in Europe against ... [Published DailyMe.Com - 46 mins ago]
FDA expands approved use of Imbruvica for chron... [Published Town Hall - 2 hours ago]
published on: 29 July, 2014 Roche's Gazyvaro ap... [Published Roche - 2 hours ago]
Merck Serono initiates phase II study of Anti-P... [Published Express Pharma - 2 hours ago]
European Commission Approves Roche's Gazyvaro F... [Published RTTNews.com - 2 hours ago]
Roche’s Gazyvaro approved in Europe for patient... [Published European Pharmaceutical Review - 3 hours ago]
EMD Serono Initiates Phase II Study Of Anti-PD-... [Published TheStreet.com - 6 hours ago]
EMD Serono Initiates Phase II Study of Anti-PD-... [Published Pettinga Financial Advisors - 6 hours ago]
EMD Serono Initiates Phase II Study of Anti-PD-... [Published Scottrade - 6 hours ago]
Roche's Gazyvaro approved in Europe for patient... [Published Noodls - 7 hours ago]
FDA Expands Approved Use of Imbruvica for Chron... [Published Drugs.com - 10 hours ago]
FDA gives full approval to ibrutinib for CLL [Published Oncology Report - 11 hours ago]
AcelRX Selling Off On FDA Reexamination; U.S. F... [Published BioMedReports - 12 hours ago]
FDA Expands Approval of Rx for Rare Blood and B... [Published Daily Rx - 13 hours ago]
In Europe, two drugs will compete to treat rare... [Published Tech Chronicles - 14 hours ago]
Pharmacyclics/Johnson & Johnson Drug Backed for... [Published Yahoo! Finance - 15 hours ago]
Gilead's Oncology Drug Recommended for Approval... [Published Zacks.com - 16 hours ago]
Diplomat receives distribution contract for Zyd... [Published Scottrade - 16 hours ago]
FDA Approves Imbruvica for Treating Chromosome ... [Published American Journal of Managed Care - 16 hours ago]
FDA OKs Imbruvica in Tough-to-Treat Form of CLL [Published MedPageToday.com - medical news plus CME for ph ... - 16 hours ago]
FDA Grants Full Approval for IMBRUVICA for Two ... [Published PharmaceuticalProcessing - 17 hours ago]
FDA expands Imbruvica approval for two CLL indi... [Published Orthopedics Today - 17 hours ago]
CHMP Recommends Pharmacyclics’ Imbruvica For 2 ... [Published Bioresearch Online - 17 hours ago]
Ibrutinib in CLL: Indication Expanded, Benefit ... [Published American Journal of Public Health - 18 hours ago]
First-Line Bendamustine Suitable for Some CLL P... [Published Diabetes Care - 18 hours ago]
U.S. FDA Grants Regular (Full) Approval for IMB... [Published Wall Street Select - 19 hours ago]
IMBRUVICA® (ibrutinib) Receives Regular Approva... [Published PR Newswire: Policy & Public Interest - 19 hours ago]
U.S. FDA Grants Regular (Full) Approval for IMB... [Published Individual.com - 19 hours ago]
U.S. FDA Grants Regular (Full) Approval for IMB... [Published PR Newswire: Policy & Public Interest - 19 hours ago]
1 2 3 4 5 6 7 8 9 10 ...
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
In Europe, two drugs will compete to treat rare... [Published Tech Chronicles - 14 hours ago]
In Europe, two Bay Area pharmaceutical companies will go head-to-head over new drugs that both treat a rare blood cancer, chronic lymphocytic leukemia, in patients whose disease has returned. Last week, Gilead Sciences of Foster City won federal approval ...
FDA OKs Imbruvica in Tough-to-Treat Form of CLL [Published MedPageToday.com - medical news plus CME for ph ... - 16 hours ago]
(MedPage Today) -- The FDA has expanded the approved use of ibrutinib (Imbruvica) in chronic lymphocytic leukemia to include patients with a chromosome 17p deletion, the agency announced today. ...
IMBRUVICA® (ibrutinib) Receives Regular Approva... [Published PR Newswire: Policy & Public Interest - 19 hours ago]
HORSHAM, Pa., July 28, 2014 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for IMBRUVICA® (ibrutinib) capsules for the treatment of patients with chronic lymphocytic leukemia (CLL) ...
U.S. FDA Grants Regular (Full) Approval for IMB... [Published PR Newswire: Policy & Public Interest - 19 hours ago]
SUNNYVALE, Calif., July 28, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that the U.S. Food and Drug Administration (FDA) has granted IMBRUVICA® (ibrutinib) regular (full) approval for the treatment of patients with chronic ...
European CHMP adopts positive opinion for Gilea... [Published PBR - News - Jul 28 2014]
Gilead Sciences has announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion on the company’s Marketing Authorization Application (MAA) for ...
1 2 3 4 5 6 7 8 9 10 ...

Press Releases

sort by: Date | Relevance
TG Therapeutics' Novel Combination of TG-1101 (... [Published GlobeNewswire: Advertising News - Jul 21 2014]
GSK and Genmab Receive EU Authorization for Arz... [Published GlobeNewswire: Nutrition News - Jul 03 2014]
TG Therapeutics Completes Global Licensing Agre... [Published GlobeNewswire: Advertising News - Jun 24 2014]
TG Therapeutics' TG-1101 (Ublituximab) in Combi... [Published GlobeNewswire: Acquisitions News - Jun 13 2014]
GSK and Genmab Receive CHMP Positive Opinion fo... [Published GlobeNewswire: Acquisitions News - May 23 2014]
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.